We are live on ! Find out more

Fluor

FLR

Market cap $7.08B

52.96 USD

-1.08

2%

At close Updated Sep 16, 2:05 PM EDT

1 day

-2%

5 days

-2.18%

1 month

-3.25%

3 months

4.56%

6 months

20.83%

Year to date

27%

1 year

29.84%

5 years

233.5%

10 years

8.93%

About: Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.

Employees: 22,995

Industrials Engineering & Construction

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 51.7%

Neutral 48.3%

Negative 0%

(PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment

CALGARY, Alberta — September 10 , 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF), a Canadian company focused on developing pharmaceutical-grade barium and iodine contrast media for medical imaging, has achieved its first milestone under a non-dilutive Collaboration and Funding Agreement with Bayer AG. The company announced that it successfully submitted a complete feasibility work plan and timetable, which has been approved by Bayer. The milestone achievement triggers the first major non-dilutive payment of USD $1,000,000 from Bayer. This payment, combined with the initial USD $350,000 received on March 31, 2026, brings the total funding received by Voyageur from Bayer to USD $1,350,000 of the committed USD $2,350,000.

(PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment

Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment

CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG (“ Bayer ”) dated February 10, 2026 (the “ Agreement ”) by submitting a complete feasibility work plan and timetable which has been approved by Bayer. (Collaboration funding news https://finance.yahoo.com/news/voyageur-pharmaceuticals-announces-collaboration-bayer-144926270.html )

Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment

Construction Firms Powering the Nuclear Renaissance

Investors usually focus on reactor developers and uranium miners when deciding on allocations for investing in the nuclear renaissance. A narrow view on the nuclear sector could result in missed opportunities for investment returns in nuclear-adjacent companies.

Construction Firms Powering the Nuclear Renaissance

Zacks Investment Research

Is Fluor (FLR) Stock Outpacing Its Construction Peers This Year?

Here is how Fluor (FLR) and James Hardie (JHX) have performed compared to their sector so far this year.

Is Fluor (FLR) Stock Outpacing Its Construction Peers This Year?

Nuclear Energy Scaling Up Through New Federal Projects

Two of the most significant government-led nuclear energy programs are illustrating how quickly the advanced nuclear field is expanding. The Nuclear Energy Launch Pad added 13 reactor and fuel cycle technology projects to its development pipeline.

Nuclear Energy Scaling Up Through New Federal Projects

Fluor Corp.: The Turnaround Is Gaining Traction, But Execution Remains The Test

Fluor Corporation is executing a multi-year turnaround, shifting to reimbursable contracts and leveraging AI to improve project execution and margins. FLR's $27B backlog is nearly 4x its $7.3B market cap, with 85% now reimbursable, reducing legacy fixed-price risk and enhancing earnings visibility. Management's modernization, AI-driven project controls, and focus on high-demand sectors—nuclear, data centers, and defense—increase FLR's strategic positioning.

Fluor Corp.: The Turnaround Is Gaining Traction, But Execution Remains The Test

DOE Backs X-Energy Texas Reactor Project With $1 Billion Support

The U.S. Department of Energy (DOE) has given X-Energy (XE) up to $1 billion in additional public funding support for its high-temperature gas-cooled reactor project in Texas. The funding marks another significant federal commitment to advancing next-generation nuclear power generation to meet growing electricity demands.

DOE Backs X-Energy Texas Reactor Project With $1 Billion Support

24/7 Wall Street

Billionaire Stanley Druckenmiller Just Bought A Top Nuclear Stock Play. George Soros Just Sold Out of It.

Three billionaires, one unglamorous engineering stock, three different answers. In Q2 2026 13F filings disclosing positions as of June 30, 2026 and filed August 14, 2026, Stanley Druckenmiller, George Soros and David Einhorn each moved on Fluor (NYSE:FLR | FLR Price Prediction), and they moved in opposite directions.

Billionaire Stanley Druckenmiller Just Bought A Top Nuclear Stock Play. George Soros Just Sold Out of It.

The Bottlenecks of the Nuclear Fuel & Supply Chain

While there is no shortage of demand from the nuclear renaissance, the rate of deploying new reactors will be determined by the capacity of the supply chain. Expanding capacity for supply chain bottlenecks, such as pump manufacturing and uranium enrichment, is not addressed overnight.

The Bottlenecks of the Nuclear Fuel & Supply Chain

Fluor Analysts Increase Their Forecasts Following Better-Than-Expected Q2 Earnings

Fluor Corporation (NYSE:FLR) on Friday reported better-than-expected second-quarter results.

Fluor Analysts Increase Their Forecasts Following Better-Than-Expected Q2 Earnings

See News Rankings

Price charts implemented using Lightweight Charts™